resminostat

DRUG2 trials

Sponsors

Yakult Honsha Co., LTD, 4SC AG

Conditions

Hepatocellular CarcinomaLymphoma, T-Cell, CutaneousMycosis FungoidesSezary Syndrome

Phase 1

Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)

CompletedNCT02400788

Yakult Honsha Co., LTDHepatocellular Carcinoma

Start: 2013-04-30End: 2016-10-31Updated: 2018-01-16

Phase 2

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)

CompletedNCT02953301

4SC AGLymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome

Start: 2016-11-30End: 2024-08-31Updated: 2024-08-30

Related Papers

S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021

JDDG Journal der Deutschen Dermatologischen Gesellschaft2022-04-0148 citations

PO-012 Pre-clinical insight into how platelet count affects the activity of HDACi resminostat in combination with the multi-kinase inhibitor sorafenib in HCC

ESMO Open2018-06-01

PO-455 Epigenetic insights: resminostat regulates targets associated with the pathogenesis of cutaneous T cell lymphoma (CTCL)

ESMO Open2018-06-01

Resminostat plus sorafenib in hepatocellular carcinoma (HCC) as apotential new treatment approach in platelet-driven solid tumors.

Journal of Clinical Oncology2018-05-201 citations

Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy.

Journal of Clinical Oncology2017-02-019 citations